NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company’s investigational […]